7 drugmakers to watch during Q3 earnings

Major themes that defined the pharma industry in the first half of 2018 carried into the third quarter. Drug pricing remained the hottest of hot-button issues, biosimilars are still threatening blockbuster brands, and restructurings revived some investor optimism — albeit at the expense of many jobs.